Amgen Boosts Outlook Despite Pressure on Some Drugs
(Bloomberg) -- Amgen Inc. boosted its financial outlook for the year, after the drugmaker posted better-than-expected results in the third quarter despite an erosion in some treatment prices.
- The company said it expects adjusted earnings per share for the full year of $16.50 to $17.10, up from a previous forecast of $16 to $17. Adjusted earnings for the third quarter were $4.67 a share, above the $4.27 Wall Street analysts were expecting.
Key Insights
- Cholesterol treatment Repatha saw sales jump 33% from a year earlier despite a lower net selling price, as volume growth surged, including a 64% jump in the U.S.
- Sales of Amgen's psoriasis drug Otezla increased 13% from a year ago despite lower prices as well. Seen as a key growth driver for Amgen, the treatment faces looming competition from Bristol Myers Squibb Co., which could bring a rival therapy to market next year.
- But Enbrel, Amgen's top-selling drug, saw sales slip 3% from the same period last year. Faced with more competition, Amgen said it expects a downward trend in the price the drug commands to continue.
- Lumakras, a new lung-cancer treatment that was cleared by U.S. regulators in May, brought in $36 million in sales in the quarter, in line with the $35.9 million expected by analysts.
Market Reaction
Amgen shares fell 1.7% in late trading in New York on Tuesday. Through the close, the stock had declined 6.8% this year.Â
Get More
- The Thousand Oaks, California-based biotech's revenue reached $6.7 billion, a 4% increase that was in-line with analyst forecasts. See more details.
- Read the statement.
©2021 Bloomberg L.P.
-
One El Nino, India Can Handle. Two Could Break The Granary
India's grain stocks can absorb one bad year, but a second El Nino could drain the buffer in two to three years, economists say.
-
India's Troika Of Good Luck | Joining The Dots
As Jensen Huang's exit drags Nvidia down, a cooling AI trade and resilient earnings have revived investor interest in India. A likely RBI rate hike looms.
-
Talking Points This Week: Leadership Shock At Nvidia, Earnings Strength, And The Fog Over Hormuz
The Anthropic IPO pricing and first trading day, Nvidia's upcoming earnings, and any fresh signals from Iran will set the tone for the following week.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.
-
Blue Wave Will Derail the AI Trade but Won't Dismantle the AI Era | Unhedged Position
The Democrats' sweep of the US Congress will see politics collide with economic forces both over the long and short term.